Jump To

FERRIPROX SIDE EFFECTS

  • Generic Name: deferiprone
  • Brand Name: Ferriprox
  • Drug Class: Chelators
Last updated on MDtodate: 10/5/2022

SIDE EFFECTS

The following clinically significant adverse reactions are described below and elsewhere in the labeling:

  • Agranulocytosis and Neutropenia
  • Liver Enzyme Elevations
  • Zinc Deficiency

Clinical Trial Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

FERRIPROX tablets (twice a day) were evaluated in trials in healthy subjects. Currently, there are no clinical data in patients with FERRIPROX tablets (twice a day). FERRIPROX tablets (twice a day) contain deferiprone, the same active ingredient as FERRIPROX (deferiprone) tablets (three times a day) and oral solution. The following adverse reaction information represents the pooled data collected from 642 patients who participated in single arm or active-controlled clinical trials taking FERRIPROX (deferiprone) tablets (three times a day) and oral solution.

The most serious adverse reaction reported in clinical trials with FERRIPROX was agranulocytosis.

The most common adverse reactions reported during clinical trials were nausea, vomiting, abdominal pain, alanine aminotransferase increased, arthralgia and neutropenia.

The table below lists the adverse drug reactions that occurred in at least 1% of patients treated with FERRIPROX in clinical trials.

Table 1:Adverse drug reactions occurring in ≥ 1% of FERRIPROX-treated patients

Body System
Adverse Reaction
(N=642)
% Subjects
BLOOD AND LYMPHATIC SYSTEM DISORDERS
  Neutropenia 6
  Agranulocytosis 2
GASTROINTESTINAL DISORDERS
  Nausea 13
  Abdominal pain/discomfort 10
  Vomiting 10
  Diarrhea 3
  Dyspepsia 2
INVESTIGATIONS
  Alanine Aminotransferase increased 7
  Weight increased 2
  Aspartate Aminotransferase increased 1
METABOLISM AND NUTRITION DISORDERS
  Increased appetite 4
  Decreased appetite 1
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS
  Arthralgia 10
  Back pain 2
  Pain in extremity 2
  Arthropathy 1
NERVOUS SYSTEM DISORDERS
  Headache 2

 

Gastrointestinal symptoms such as nausea, vomiting, and abdominal pain were the most frequent adverse reactions reported by patients participating in clinical trials and led to the discontinuation of FERRIPROX therapy in 1.6% of patients.

Chromaturia (reddish/brown discoloration of the urine) is a result of the excretion of iron in the urine.

Postmarketing Experience

The following additional adverse reactions have been reported in patients receiving FERRIPROX. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or to establish a causal relationship to drug exposure.

Blood and lymphatic system disorders: thrombocytosis, pancytopenia.

Cardiac disorders: atrial fibrillation, cardiac failure.

Congenital, familial and genetic disorders: hypospadias.

Eye disorders: diplopia, papilledema, retinal toxicity.

Gastrointestinal disorders: enterocolitis, rectal hemorrhage, gastric ulcer, pancreatitis, parotid gland enlargement.

General disorders and administration site conditions: chills, pyrexia, edema peripheral, multi-organ failure.

Hepatobiliary disorders: jaundice, hepatomegaly.

Immune system disorders: anaphylactic shock, hypersensitivity.

Infections and infestations: cryptococcal cutaneous infection, enteroviral encephalitis, pharyngitis, pneumonia, sepsis, furuncle, infectious hepatitis, rash pustular, subcutaneous abscess.

Investigations: blood bilirubin increased, blood creatinine phosphokinase increased.

Metabolism and nutrition disorders: metabolic acidosis, dehydration.

Musculoskeletal and connective tissue disorders: myositis, chondropathy, trismus.

Nervous system disorders: cerebellar syndrome, cerebral hemorrhage, convulsion, gait disturbance, intracranial pressure increased, psychomotor skills impaired, pyramidal tract syndrome, somnolence.

Psychiatric disorders: bruxism, depression, obsessive-compulsive disorder.

Renal disorders: glycosuria, hemoglobinuria.

Respiratory, thoracic and mediastinal disorders: acute respiratory distress syndrome, epistaxis, hemoptysis, pulmonary embolism.

Skin, subcutaneous tissue disorders: hyperhidrosis, periorbital edema, photosensitivity reaction, pruritis, urticaria, rash, Henoch-Schönlein purpura.

Vascular disorders: hypotension, hypertension.

 

SRC: NLM .

Read Next Article

PHP Code Snippets Powered By : XYZScripts.com